DOD Chronic Pain Management, Investigator-Initiated Research Award | W81XWH 21 CPMRP IIRA

Opportunity Information: Apply for W81XWH 21 CPMRP IIRA

The DOD Chronic Pain Management, Investigator-Initiated Research Award (FY21 CPMRP IIRA) is a Department of Defense funding opportunity designed to back investigator-driven research that can meaningfully move the needle in chronic pain management. The core goal is to fund studies that are likely to produce significant advances in research knowledge, improve patient care, and/or enhance quality of life, specifically within the program's FY21 focus areas. The emphasis is on impactful, well-justified projects where the research question and approach are strong enough to plausibly shift understanding or practice, rather than incremental work.

The program is intentionally broad in the types of research it will consider. Proposals can be basic science, translational, or clinically oriented, and may include studies using animal models, human anatomical substances, or human participants. It also allows correlative or ancillary studies that are tied to an already-existing clinical trial, meaning you can leverage samples, data, or observations connected to a trial that is happening elsewhere or under separate support. At the same time, a key restriction is that this award mechanism cannot be used to run a clinical trial itself. In practical terms, applicants need to design projects that stay on the research side of discovery, mechanism, measurement, validation, or implementation support, without crossing into funding an interventional clinical trial as the primary activity under this award.

The opportunity encourages multidisciplinary collaboration and innovative approaches, signaling that competitive applications will often bring together expertise across fields (for example, pain medicine, rehabilitation, neuroscience, psychology, bioengineering, data science, or health services research) and may apply novel methods, technologies, or integrative frameworks. The intent is to foster research that can lead to real advances, including potentially new ways of understanding chronic pain, improving management strategies, refining diagnostics or phenotyping, or strengthening non-opioid and systems-based approaches to care.

A major boundary of the program involves opioids. Projects aimed at developing new or novel opioid-based therapeutic interventions are explicitly considered outside the intent of the award and may be withdrawn from consideration. However, opioid-related work is not categorically excluded: studies that focus on understanding opioid use and reducing opioid utilization in chronic pain management are acceptable when framed within current prescribing practices. That means research questions centered on opioid stewardship, risk reduction, tapering strategies, alternatives that reduce reliance on opioids, or clinical and behavioral factors influencing opioid use can fit, as long as the work is not essentially proposing a new opioid therapy.

Administratively, this FY21 opportunity was offered by the Department of Defense, Department of the Army, through USAMRAA, and was listed under CFDA 12.420 within science and technology and other research and development. It allowed funding through either a grant or cooperative agreement mechanism. Eligibility was described as unrestricted, open to any type of entity, subject to any additional eligibility language in the full announcement. The opportunity opened in mid-June 2021 and had an original closing date of November 12, 2021. The listing indicated an expectation of about five awards, and the award ceiling was shown as 0 in the source data, which typically implies that the maximum award amount was not specified in the summary field and would need to be confirmed in the full funding announcement or program guidelines.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Chronic Pain Management, Investigator-Initiated Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jun 15, 2021.
• Applicants must submit their applications by Nov 12, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 CPMRP IIRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: